NUMIF - Numinus Wellness Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.1666 |
| Open | 0.1520 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.1455 - 0.1669 |
| 52 Week Range | 0.1050 - 0.3110 |
| Volume | |
| Avg. Volume | 90,928 |
| Market Cap | 39.247M |
| Beta (5Y Monthly) | 2.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1200 |
| Earnings Date | Jul 12, 2023 - Jul 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.50 |
Fair Value
Related Research
CNW GroupNuminus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023, at 1:00 p.m. ET / 10:00 a.m. PT.
PR NewswireNuminus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study
Numinus Wellness Inc. (TSX: NUMI) is pleased to announce that Cedar Clinical Research (CCR) has begun studying COMP360 psilocybin therapy, an investigational new therapy for treatment-resistant depression (TRD), as part of the largest-ever international clinical study of psilocybin therapy. Dr. Paul Thielking, Chief Science Officer at Numinus, and the team have begun accepting people with TRD who fulfill certain eligibility criteria to join the study.
PR NewswireNuminus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce several recent initiatives aimed at best positioning the company for the expected FDA approval of MDMA-assisted therapy ("MDMA-AT") in the United States in the first half of 2024. In anticipation of this regulatory approval, Numinus has undertaken several initiatives to prepare t
ACCESSWIREThe Power Play by The Market Herald Releases New Interviews with Reunion Gold Corp, Numinus Wellness, Core Assets, Blockmate Ventures, BioVaxys Tech, Carlyle Commodities and Belmont Resources Discussing Their Latest News
The Power Play by The Market Herald has announced the release of new interviews with Reunion Gold Corp, Numinus Wellness, Core Assets, Blockmate Ventures, BioVaxys Tech, Carlyle Commodities and Belmont Resources discussing their latest news.
CNW GroupNuminus to Participate in a Water Tower Research Fireside Chat on Wednesday, April 19, 2023
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, April 19, 2023, at 11:30 a.m. ET / 8:30 a.m. PT.
PR NewswireNuminus Launches New Website to Enhance its Client Experience
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched a new client website at www.numinus.com as part of its branding strategy to align all wellness clinics under the Numinus brand.
PR NewswireNuminus Wellness Inc. Reports Q2 2023 Results
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three and six months ended February 28, 2023 ("Q2 2023" and "first six months").
- Newsfile
Healing CREI Announces a Partnership with Numinus Wellness Inc.
Lake Worth, Florida--(Newsfile Corp. - April 11, 2023) - Healing Commercial Real Estate Inc. ("Healing CREI" or the "Company"), a data-driven self-managed real estate investment company, today announced that the Company has entered into a partnership with Numinus Wellness Inc. (TSX: NUMI) ("Numinus"), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies to support their newly launched clinic licensing model, named the Numinus Networ
PR NewswireNuminus Launches new Clinic Licensing Platform, the Numinus Network, to Accelerate Expansion
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched a new clinic licensing model, named the Numinus Network, offering independent practitioners the opportunity to own and operate their own clinic under the trusted Numinus Wellness brand through a licensing and services arrangement. As a leader in the mental health ca
PR NewswireNuminus to Host Q2 2023 Results Conference Call on April 13, 2023
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended February 28, 2023, after market close on Thursday, April 13, 2023.
PR NewswireNuminus Launches the Practitioner Certification Pathway - a Complete Psychedelic-Assisted Therapy Training Program
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched the Numinus Certification Pathway – a collection of psychedelic-assisted therapy ("PAT") training courses uniquely selected to provide practitioners with complete PAT training, including an experiential component and practicum.
PR NewswireNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Sequire Cannabis & Psychedelics Conference to be held virtually on Wednesday, April 5, 2023.
PR NewswireNuminus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Reid Robison, Chief Clinical Officer of Numinus, has contributed to studies published in four peer-reviewed papers thus far in 2023 for his work in the treatment of mental health disorders including Post-Traumatic Stress Disorder (PTSD), depression, and anxiety.
CNW GroupNuminus Wellness Inc. Executives to Present on Panel at Upcoming South by Southwest Conference
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will be featured on a panel at the upcoming South by Southwest Conference taking place in Austin, Texas, on March 10 - 19, 2023. The panel, titled Music as Medicine: Music as a Tool for Healing, will be held on March 10, 2023 at 4:00pm CT at the Austin Convention Center. For more information on SXSW and the panel, please click her
PR NewswireNuminus to Participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Dr. Paul Thielking, Chief Science Officer of Numinus, will participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023, at 3:00 p.m. ET / 12:00 p.m. PT.
CNW GroupNuminus Expands Research Capabilities with new Phoenix Clinical Research Site
Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has expanded its clinical research capabilities into Arizona. The site, located in Phoenix where Numinus operates mental health clinics, is Numinus' third clinical trial research site in the US, and fifth research site overall. It will offer clinical research management services, focused on adva
CNW GroupNuminus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting"), held earlier today. A total of 43,610,863 common shares representing 16.6% of the 262,749,836 issued and outstanding common shares of the Company as at the record date of January 16, 2
PR NewswireNuminus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has received approval from Health Canada for its experiential training study that will test the safety and clinical efficacy of whole Psilocybe cubensis tea for therapeutic use, and enable practitioners to further their understanding of psychedelic-assisted therapy through exper
CNW GroupNuminus Wellness Inc. Reports Q1 2023 Results
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended November 30, 2022 ("Q1 2023").
PR NewswireNuminus to Host Q1 2023 Results Conference Call on January 16, 2023
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended November 30, 2022, after market close on Monday, January 16, 2023.
GlobeNewswireKCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the presentations from its KCSA Mental Health Virtual Investor Conference held on December 15th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3FPSRgWThe company presentations will be
- GlobeNewswire
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Mental Health Virtual Investor Conference to be held on Thursday, December 15, 2022. Individual investors, institutional investors, advisors, and analysts are invited to atte
CNW GroupNuminus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will present at the KCSA Mental Health Investor Conference to be held at VirtualInvestorConferences.com on Thursday, December 15, 2022 at 12:30 p.m. ET / 9:30 a.m. PT.
CNW GroupNuminus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its research division has submitted a clinical trial application to Health Canada to begin a new experiential training study that will enable practitioners training to provide Psilocybin-Assisted Therapy (PAT) the ability to experience and observe psilocybin sessions to further the